SAN ANTONIO - New data suggest that adjuvant treatment with the bisphosphonate zoledronic acid (Zometa) plus chemotherapy may have a direct anti-tumor effect in women with breast cancer who are at high risk of a relapse. The findings were reported here at the 2008 San Antonio Breast Cancer Symposium (SABCS).
More...